Characteristics and Renal Toxicity Profile of Patients with mCRPC and Single Functioning Kidney (n = 16)
| Characteristic | Data |
| Age (y) | 64.7 ± 6.5 |
| Weight (kg) | 84.6 ± 14.0 |
| Karnofsky performance status | 82.5 ± 11.8 (range, 60–100) |
| Primary treatment before PRLT | |
| Radical prostatectomy | 9 (56.3%) |
| External-beam radiotherapy | 6 (37.5%) |
| Androgen deprivation therapy | 16 (100.0%) |
| Chemotherapy | 12 (75.0%) |
| Docetaxel | 7 (43.8%) |
| Cabazitaxel | 3 (18.8%) |
| Docetaxel and cabazitaxel | 2 (12.5%) |
| Denosumab | 2 (12.5%) |
| Phosphoinositide 3-kinase inhibitor | 1 (6.3%) |
| mTOR inhibitor | 1 (6.3%) |
| Renal function (CTCAE) at baseline | |
| Grade 0 | 9 (56.3%) |
| Grade 1 | 4 (25.0%) |
| Grade 2 | 3 (18.8%) |
| Grade 3 | 0 (0.0%) |
| Grade 4 | 0 (0.0%) |
| Renal function (CTCAE) after first cycle of treatment | |
| Grade 0 | 9 (56.3%) |
| Grade 1 | 6 (37.5%) |
| Grade 2 | 1 (6.3%) |
| Grade 3 | 0 (0.0%) |
| Grade 4 | 0 (0.0%) |
| Renal function (CTCAE) after second cycle of treatment | |
| Grade 0 | 9 (56.3%) |
| Grade 1 | 5 (31.3%) |
| Grade 2 | 2 (12.5%) |
| Grade 3 | 0 (0.0%) |
| Grade 4 | 0 (0.0%) |
| TER using 99mTc-MAG3 renal scintigraphy | |
| At baseline | 135.6 ± 47.3 |
| After last treatment | 127.1 ± 41.5 |
| TER/TERLoLi ratio | |
| At baseline | 0.81 ± 0.31 |
| After last treatment | 0.80 ± 0.28 |
MAG3 = mercaptoacetyltriglycine.